Details of the Drug

General Information of Drug (ID: DM804UR)

Drug Name
Hyoscyamine
Synonyms
L-Hyoscyamine; hyoscyamine; 101-31-5; (-)-Hyoscyamine; Daturine; Duboisine; (-)-Atropine; L-Tropine tropate; (S)-Atropine; (S)-(-)-Hyoscyamine; Hyoscyamine (L); UNII-PX44XO846X; Tropine, (-)-tropate; Levbid; PX44XO846X; Levsinex SR; CHEBI:17486; Hyoscyamine, l-; [3(S)-endo]-alpha-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; (2S)-(1R,5S)-8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropanoate; (1R,5S)-8-METHYL-8-AZABICYCLO[321]OCT-3-YL (2R)-3-HYDROXY-2-PHENYLPROPANOATE; Hyocyamine
Indication
Disease Entry ICD 11 Status REF
Gastrointestinal disease DE2Z Approved [1]
Therapeutic Class
Antiarrhythmic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 289.4
Topological Polar Surface Area (xlogp) 1.8
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Elimination
57% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.5 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0046 micromolar/kg/day [4]
Water Solubility
The ability of drug to dissolve in water is measured as 3.56 mg/mL [2]
Chemical Identifiers
Formula
C17H23NO3
IUPAC Name
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate
Canonical SMILES
CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3
InChI
InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16-/m1/s1
InChIKey
RKUNBYITZUJHSG-VFSICIBPSA-N
Cross-matching ID
PubChem CID
154417
ChEBI ID
CHEBI:17486
CAS Number
101-31-5
DrugBank ID
DB00424
TTD ID
D0RD5W

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M5 (CHRM5) TTH18TF ACM5_HUMAN Antagonist [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Hyoscyamine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Mepenzolate. Digestive system disease [DE2Z] [16]
Coadministration of a Drug Treating the Disease Different from Hyoscyamine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Moderate Antagonize the effect of Hyoscyamine when combined with Bethanechol. Abnormal micturition [MF50] [17]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Hyoscyamine and Oliceridine. Acute pain [MG31] [18]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Scopolamine. Addictive disorder [6C50-6C5Z] [16]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [19]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [19]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [16]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Memantine. Alzheimer disease [8A20] [16]
Galantamine DMEO794 Moderate Antagonize the effect of Hyoscyamine when combined with Galantamine. Alzheimer disease [8A20] [20]
Rivastigmine DMG629M Moderate Antagonize the effect of Hyoscyamine when combined with Rivastigmine. Alzheimer disease [8A20] [20]
Donepezil DMIYG7Z Moderate Antagonize the effect of Hyoscyamine when combined with Donepezil. Alzheimer disease [8A20] [20]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [16]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Desipramine. Attention deficit hyperactivity disorder [6A05] [16]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Cariprazine. Bipolar disorder [6A60] [16]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Hyoscyamine and Loperamide. Bowel habit change [ME05] [21]
Sotalol DML60TN Moderate Antagonize the effect of Hyoscyamine when combined with Sotalol. Cardiac arrhythmia [BC9Z] [22]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Hyoscyamine when combined with Acetylcholine. Cataract [9B10] [23]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [24]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [24]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [24]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Hyoscyamine and Olopatadine. Conjunctiva disorder [9A60] [25]
Alfentanil DMVO0UB Moderate Additive antimotility effects by the combination of Hyoscyamine and Alfentanil. Corneal disease [9A76-9A78] [26]
Arbutamine DMCY8AF Moderate Increased risk of rapid heart rate by the combination of Hyoscyamine and Arbutamine. Coronary atherosclerosis [BA80] [27]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Hyoscyamine and Ethanol. Cystitis [GC00] [28]
Trimipramine DM1SC8M Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Trimipramine. Depression [6A70-6A7Z] [16]
Imipramine DM2NUH3 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Imipramine. Depression [6A70-6A7Z] [16]
Nortriptyline DM4KDYJ Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Nortriptyline. Depression [6A70-6A7Z] [16]
Isocarboxazid DMAF1NB Minor Additive anticholinergic effects by the combination of Hyoscyamine and Isocarboxazid. Depression [6A70-6A7Z] [16]
Tranylcypromine DMGB5RE Minor Additive anticholinergic effects by the combination of Hyoscyamine and Tranylcypromine. Depression [6A70-6A7Z] [16]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Hyoscyamine and OPC-34712. Depression [6A70-6A7Z] [16]
Phenelzine DMHIDUE Minor Additive anticholinergic effects by the combination of Hyoscyamine and Phenelzine. Depression [6A70-6A7Z] [16]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Clomipramine. Depression [6A70-6A7Z] [16]
Amoxapine DMKITQE Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Amoxapine. Depression [6A70-6A7Z] [16]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Doxepin. Depression [6A70-6A7Z] [19]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Maprotiline. Depression [6A70-6A7Z] [16]
Nitroglycerin DMQ2491 Minor Decreased dissolution of Hyoscyamine taken sublingually caused by Nitroglycerin. Diabetic foot ulcer [BD54] [29]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Oxybutynine. Discovery agent [N.A.] [16]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Meclizine. Dizziness and giddiness [MB48] [16]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Hyoscyamine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [30]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Diphenhydramine. Episodic vestibular syndrome [AB31] [16]
Bendroflumethiazide DM7EVLC Minor Altered absorption of Hyoscyamine due to GI dynamics variation caused by Bendroflumethiazide. Essential hypertension [BA00] [31]
Benzthiazide DMQWZ0H Minor Altered absorption of Hyoscyamine due to GI dynamics variation caused by Benzthiazide. Essential hypertension [BA00] [31]
Nadolol DMW6GVL Moderate Antagonize the effect of Hyoscyamine when combined with Nadolol. Essential hypertension [BA00] [22]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Solifenacin. Functional bladder disorder [GC50] [16]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Tolterodine. Functional bladder disorder [GC50] [16]
Darifenacin DMWXLYZ Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Darifenacin. Functional bladder disorder [GC50] [16]
Ketoconazole DMPZI3Q Moderate Decreased absorption of Hyoscyamine due to altered gastric pH caused by Ketoconazole. Fungal infection [1F29-1F2F] [32]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Propantheline. Gastric ulcer [DA60] [16]
Cisapride DMY7PED Moderate Antagonize the effect of Hyoscyamine when combined with Cisapride. Gastro-oesophageal reflux disease [DA22] [33]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Hyoscyamine when combined with Isoflurophate. Glaucoma [9C61] [23]
Carteolol DMFMDOB Moderate Antagonize the effect of Hyoscyamine when combined with Carteolol. Glaucoma [9C61] [22]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Hyoscyamine when combined with Pilocarpine. Glaucoma [9C61] [17]
Carvedilol DMHTEAO Moderate Altered absorption of Hyoscyamine due to GI dynamics variation caused by Carvedilol. Heart failure [BD10-BD1Z] [34]
Chlorothiazide DMLHESP Minor Altered absorption of Hyoscyamine due to GI dynamics variation caused by Chlorothiazide. Heart failure [BD10-BD1Z] [31]
Hydroflumethiazide DMVPUQI Minor Altered absorption of Hyoscyamine due to GI dynamics variation caused by Hydroflumethiazide. Heart failure [BD10-BD1Z] [31]
Acebutolol DM0TI4U Moderate Altered absorption of Hyoscyamine due to GI dynamics variation caused by Acebutolol. Hypertension [BA00-BA04] [34]
Bisoprolol DM3UZ95 Moderate Altered absorption of Hyoscyamine due to GI dynamics variation caused by Bisoprolol. Hypertension [BA00-BA04] [34]
Penbutolol DM4ES8F Moderate Antagonize the effect of Hyoscyamine when combined with Penbutolol. Hypertension [BA00-BA04] [22]
Nebivolol DM7F1PA Moderate Antagonize the effect of Hyoscyamine when combined with Nebivolol. Hypertension [BA00-BA04] [22]
Pindolol DMD2NV7 Moderate Antagonize the effect of Hyoscyamine when combined with Pindolol. Hypertension [BA00-BA04] [22]
Indapamide DMGN1PW Minor Altered absorption of Hyoscyamine due to GI dynamics variation caused by Indapamide. Hypertension [BA00-BA04] [31]
Trichlormethiazide DMHAQCO Minor Altered absorption of Hyoscyamine due to GI dynamics variation caused by Trichlormethiazide. Hypertension [BA00-BA04] [31]
Hydrochlorothiazide DMUSZHD Minor Altered absorption of Hyoscyamine due to GI dynamics variation caused by Hydrochlorothiazide. Hypertension [BA00-BA04] [31]
Potassium chloride DMMTAJC Major Increased risk of GI mucosal injury/bleeding risk by the combination of Hyoscyamine and Potassium chloride. Hypo-kalaemia [5C77] [35]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Belladonna. Infectious gastroenteritis/colitis [1A40] [16]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Amantadine. Influenza [1E30-1E32] [36]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Propiomazine. Insomnia [7A00-7A0Z] [16]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Hyoscyamine and ITI-007. Insomnia [7A00-7A0Z] [16]
R0-93877 DMM4U9G Moderate Antagonize the effect of Hyoscyamine when combined with R0-93877. Irritable bowel syndrome [DD91] [37]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Clidinium. Irritable bowel syndrome [DD91] [16]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Dicyclomine. Irritable bowel syndrome [DD91] [16]
Physostigmine DM2N0TO Moderate Antagonize the effect of Hyoscyamine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [20]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Hyoscyamine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [38]
Propranolol DM79NTF Moderate Antagonize the effect of Hyoscyamine when combined with Propranolol. Migraine [8A80] [22]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Hyoscyamine and Lasmiditan. Migraine [8A80] [39]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Hyoscyamine and Flibanserin. Mood disorder [6A60-6E23] [40]
Neostigmine DM6T2J3 Moderate Antagonize the effect of Hyoscyamine when combined with Neostigmine. Myasthenia gravis [8C6Y] [41]
Pyridostigmine DM8HO1L Moderate Antagonize the effect of Hyoscyamine when combined with Pyridostigmine. Myasthenia gravis [8C6Y] [41]
Edrophonium DMCRQHB Moderate Antagonize the effect of Hyoscyamine when combined with Edrophonium. Myasthenia gravis [8C6Y] [41]
Ambenonium DMOP0BL Moderate Antagonize the effect of Hyoscyamine when combined with Ambenonium. Myasthenia gravis [8C6Y] [41]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Phenindamine. Nasopharyngitis [CA00] [16]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Dimenhydrinate. Nausea/vomiting [MD90] [16]
Prochlorperazine DM53SRA Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Prochlorperazine. Nausea/vomiting [MD90] [16]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Promethazine. Nausea/vomiting [MD90] [16]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Cyclizine. Nausea/vomiting [MD90] [16]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Hyoscyamine when combined with Metoclopramide. Nausea/vomiting [MD90] [42]
Metolazone DMB39LO Minor Altered absorption of Hyoscyamine due to GI dynamics variation caused by Metolazone. Oedema [MG29] [31]
Polythiazide DMCH80F Minor Altered absorption of Hyoscyamine due to GI dynamics variation caused by Polythiazide. Oedema [MG29] [31]
Levomethadyl Acetate DM06HG5 Moderate Additive CNS depression effects by the combination of Hyoscyamine and Levomethadyl Acetate. Opioid use disorder [6C43] [43]
Pentazocine DM1XBHS Moderate Additive CNS depression effects by the combination of Hyoscyamine and Pentazocine. Pain [MG30-MG3Z] [18]
Dextropropoxyphene DM23HCX Moderate Additive antimotility effects by the combination of Hyoscyamine and Dextropropoxyphene. Pain [MG30-MG3Z] [43]
Butorphanol DM5KYPJ Moderate Additive antimotility effects by the combination of Hyoscyamine and Butorphanol. Pain [MG30-MG3Z] [26]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Hyoscyamine and Oxymorphone. Pain [MG30-MG3Z] [18]
Levorphanol DMGS80V Moderate Additive antimotility effects by the combination of Hyoscyamine and Levorphanol. Pain [MG30-MG3Z] [18]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Hyoscyamine and Dezocine. Pain [MG30-MG3Z] [18]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Flavoxate. Pain [MG30-MG3Z] [16]
Nalbuphine DMOSQGU Moderate Additive antimotility effects by the combination of Hyoscyamine and Nalbuphine. Pain [MG30-MG3Z] [18]
Buprenorphine DMPRI8G Moderate Additive antimotility effects by the combination of Hyoscyamine and Buprenorphine. Pain [MG30-MG3Z] [26]
Hydrocodone DMQ2JO5 Moderate Additive antimotility effects by the combination of Hyoscyamine and Hydrocodone. Pain [MG30-MG3Z] [18]
Meperidine DMX4GND Moderate Additive antimotility effects by the combination of Hyoscyamine and Meperidine. Pain [MG30-MG3Z] [18]
Oxycodone DMXLKHV Moderate Additive CNS depression effects by the combination of Hyoscyamine and Oxycodone. Pain [MG30-MG3Z] [18]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Biperiden. Parkinsonism [8A00] [16]
Levodopa DMN3E57 Moderate Altered absorption of Hyoscyamine due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [44]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Orphenadrine. Parkinsonism [8A00] [16]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Methylscopolamine. Peptic ulcer [DA61] [16]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Levomepromazine. Psychotic disorder [6A20-6A25] [16]
Fluphenazine DMIT8LX Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Fluphenazine. Psychotic disorder [6A20-6A25] [16]
Triflupromazine DMKFQJP Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Triflupromazine. Psychotic disorder [6A20-6A25] [16]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Cyproheptadine. Rheumatoid arthritis [FA20] [16]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Mesoridazine. Schizophrenia [6A20] [16]
Thioridazine DM35M8J Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Thioridazine. Schizophrenia [6A20] [16]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Aripiprazole. Schizophrenia [6A20] [16]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Paliperidone. Schizophrenia [6A20] [16]
Haloperidol DM96SE0 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Haloperidol. Schizophrenia [6A20] [16]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Perphenazine. Schizophrenia [6A20] [16]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Molindone. Schizophrenia [6A20] [16]
Chlorpromazine DMBGZI3 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Chlorpromazine. Schizophrenia [6A20] [16]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Thiothixene. Schizophrenia [6A20] [16]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Trifluoperazine. Schizophrenia [6A20] [16]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Risperidone. Schizophrenia [6A20] [16]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Asenapine. Schizophrenia [6A20] [16]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Pimozide. Schizophrenia [6A20] [16]
Fentanyl DM8WAHT Moderate Additive antimotility effects by the combination of Hyoscyamine and Fentanyl. Sensation disturbance [MB40] [26]
Sufentanil DMU7YEL Moderate Additive CNS depression effects by the combination of Hyoscyamine and Sufentanil. Sensation disturbance [MB40] [18]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Hyoscyamine and Tizanidine. Tonus and reflex abnormality [MB47] [45]
Pramlintide DM0EZ9Q Moderate Altered absorption of Hyoscyamine due to GI dynamics variation caused by Pramlintide. Type-1/2 diabete [5A10-5A11] [46]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Atropine. Unspecific substance harmful effect [NE6Z] [16]
Nitrofurantoin DM7PQIK Minor Altered absorption of Hyoscyamine due to GI dynamics variation caused by Nitrofurantoin. Urinary tract infection [GC08] [47]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [16]
Triprolidine DM7SWIA Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Triprolidine. Vasomotor/allergic rhinitis [CA08] [16]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [16]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [16]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [19]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [16]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [16]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Hyoscyamine and Azatadine. Vasomotor/allergic rhinitis [CA08] [16]
⏷ Show the Full List of 135 DDI Information of This Drug

References

1 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
2 BDDCS applied to over 900 drugs
3 Dailymed: Hyoscyamine Subcutaneous Injection
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Reconstitution of the purified porcine atrial muscarinic acetylcholine receptor with purified porcine atrial inhibitory guanine nucleotide binding protein. Biochemistry. 1987 Dec 15;26(25):8175-82.
6 Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.
7 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
8 Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6.
9 Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
10 Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204.
11 Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354).
13 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
14 Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7.
15 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
16 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
17 Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
18 Product Information. Levorphanol Tartrate (levorphanol). Sentynl Therapeutics, Solana Beach, CA.
19 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
20 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
21 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
22 Cerner Multum, Inc. "Australian Product Information.".
23 Multum Information Services, Inc. Expert Review Panel.
24 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
25 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
26 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
27 Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA.
28 Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12. [PMID: 4588850]
29 Product Information. Nitrostat (nitroglycerin). Parke-Davis, Morris Plains, NJ.
30 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
31 Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
32 Fleseriu M, Auchus R, Pivonello R, et al. "Levoketoconazole: a novel treatment for endogenous Cushing's syndrome.".
33 Product Information. Propulsid (cisapride). Janssen Pharmaceutica, Titusville, NJ.
34 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
35 Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
36 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
37 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
38 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
39 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
40 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
41 Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
42 Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
43 Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
44 Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
45 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
46 Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.
47 Jaffe JM "Effect of propantheline on nitrofurantoin absorption." J Pharm Sci 64 (1975): 1729-30. [PMID: 1185550]